Next generation genomic technologies have made a significant contribution to the understanding of the genetic architecture of human neurodevelopmental disorders. Copy number variants (CNVs) play an important role in the genetics of intellectual disability (ID). For many CNVs, and copy number gains in particular, the responsible dosage-sensitive gene(s) have been hard to identify. We have collected 18 different interstitial microduplications and 1 microtriplication of Xq25. There were 15 affected individuals from 6 different families and 13 singleton cases, 28 affected males in total. The critical overlapping region involved the STAG2 gene, which codes for a subunit of the cohesin complex that regulates cohesion of sister chromatids and gene transcription. We demonstrate that STAG2 is the dosage-sensitive gene within these CNVs, as gains of STAG2 mRNA and protein dysregulate disease-relevant neuronal gene networks in cells derived from affected individuals. We also show that STAG2 gains result in increased expression of OPHN1, a known X-chromosome ID gene. Overall, we define a novel cohesinopathy due to copy number gain of Xq25 and STAG2 in particular.
Introduction
Intellectual disability (ID) is a heterogeneous neurodevelopmental disorder (NDD) of major societal and personal importance. It is at least 50% genetic, and the underlying etiology is complex and highly heterogeneous with thousands of genes and loci likely involved. It is estimated that copy number variants (CNVs) are responsible for ∼21-25% of individuals with ID (1, 2) . Determining the clinical significance of CNVs is challenging, in particular those involving the X chromosome (3) . Chromosome X duplications may lead to disease in males due to functional disomy of the duplicated genes (4) . Depending on the pattern of X chromosome inactivation, heterozygous females can also be variably affected (5) . Array comparative genomic hybridization (aCGH) detects X-chromosome CNVs in 0-5% of unselected individuals with NDDs (3). Of these, duplications of Xq28 including MECP2 are the most frequent (6) . In addition, duplications of Xq25 encompassing part (7) (8) (9) or all (10) of GRIA3, an established XLID gene (11, 12) , have been associated with clinically variable ID phenotype. More recently, Xq25 duplications involving THOC2, XIAP, STAG2 or SH2D1A, which are located distal to GRIA3, have been implicated in ID (10, (13) (14) (15) . However, the dosage-sensitive gene or genes driving the disease phenotype in affected individuals have remained elusive. Here, we present data from systematic and in-depth clinical and molecular studies of 28 affected males (15 from 6 unrelated families and 13 singleton cases) harboring Xq25 microduplications and one case of a triplication showing that STAG2 is the dosage-sensitive gene in the affected individuals. Our results define a novel cohesinopathy due to copy number gain of Xq25 and STAG2 in particular.
Results

STAG2 copy number gains are implicated in intellectual disability and behavioral problems
Initially, we identified Xq25 microduplications and one microtriplication in six unrelated index males with ID and various additional clinical features through aCGH (families NSW, SA1 and SA2) and Xchromosome exome sequencing as previously described (16) (17) (18) (families D57, D166 and L70). The duplicated regions varied from 202 to 746 kb in length and contained THOC2-XIAP-STAG2, XIAP-STAG2 or partial XIAP and STAG2. The triplicated region contained XIAP and STAG2 (Fig. 1A) . We confirmed the copy number gains by quantitative polymerase chain reaction (qPCR), high-resolution aCGH and fluorescent in situ hybridization (FISH), and where available, tested their segregation in extended pedigrees ( Fig. 2 and data available on request). All procedures followed were in accordance with the ethical standards of the appropriate institutional Human Research Ethics Committees, and proper informed consent was obtained.
Subsequently, we evaluated ∼27 000 males with neurodevelopmental delay and/or congenital anomalies (and 6459 male controls) referred for clinical aCGH testing and identified an additional 13 sporadic singleton cases with a duplication encompassing STAG2. In addition to STAG2, GRIA3 was duplicated in one, THOC2 in two, XIAP in six and SH2D1A in one individual ( Fig. 1B ; Signature Genomics and Baylor College of Medicine). In addition, three individuals with only STAG2 and one individual with STAG2-SH2D1A and partial TENM1 duplication were identified in the DECIPHER database (Fig. 1B) . Taken together, we show that in all affected individuals, the critical region contains STAG2. This led us to hypothesize that STAG2 gains might play a role in abnormal development and that STAG2 is the disease-relevant gene in Xq25 duplications (7) (8) (9) (10) 13, 14) , and not GRIA3 as previously speculated (7, 10) . To test our hypothesis of the importance of STAG2 dosage for normal neuronal development, we clinically evaluated all affected individuals from the initial six families and compared them with previously published cases. We also performed STAG2 expression analysis at the mRNA and protein level using cells derived from affected individuals.
The clinical details of our and published cases with Xq25 microduplications and their family members (total 43; males 33) are presented in Table 1 and Supplementary Material, Table S1 . Clinical description of the SA1 family with Xq25 triplication is highlighted in Supplementary Material, Table S1 . Photographs of the affected individuals are shown in Figure 2 . We have also reviewed the clinical findings of 18 males from the literature together with the DECIPHER cases 250 183 and 270 242 (7, 10, (13) (14) (15) 19) , who all carry an Xq25 duplication encompassing STAG2. All males with Xq25 duplications presented with some degree of ID, mostly mild-moderate ID. Of the carrier females (n = 10), one had mild ID, six were described as having borderline ID or delays and the remaining three had normal cognitive function. Behavioral problems such as anxiety, hyperactivity and aggressive behavior were noted in 68% (19/28) of all affected males. Autism spectrum disorder was reported in four males. Short stature was noted in 21% (6/28) of cases for whom information was available. Head circumference was typically in the normal range. Seizures were only noted in 32% (10/31) males, excepting one female. Brain imaging was performed in 10 individuals; 4 were reported as normal and among the 6 with abnormalities, cerebellar vermis hypoplasia were noted in 4, a thin corpus callosum in 3 and prominent subarachnoid spaces in 2. Facial features were not clearly documented in all cases; however, there is evidence of a subtle, but consistent phenotype including malar flatness, full lips and prognathia was present in 23/27, 15/26 and 16/26, respectively. Recently, clinical information and photographs of six affected children carrying STAG2 duplications has been reported (19) , and many of the features overlap with adult faces shown here, although the thin arched eyebrows and facial hypotonia are less apparent with age.
The affected male of family SA1 who carries a triplication of XIAP and STAG2 had a more severe clinical phenotype compared with individuals with Xq25 duplication. He presented with severe ID, stereotypies, obsessive-compulsive behavior, anxiety and aggressive outbursts. He was dysmorphic, with a broad forehead, frontal bossing, small posteriorly rotated low-set ears, long nose, smooth philtrum, wide spaced teeth, gum hypertrophy, facial hypotonia, short distal phalanges of fingers and 2-3 toes syndactyly. He also had hypermetropia, tight Achilles tendons and valgus foot deformity. Imaging demonstrated cone-shaped epiphyses of toes 2-4 and mild cerebral ventricular enlargement with prominent subarachnoid spaces. The mother, who has four copies of the region, had slightly skewed X-inactivation (85:15) and had borderline ID and schizophrenia.
STAG2 and XIAP but not THOC2 protein levels reflect their copy number gains in patient-derived cells
To identify the dosage-sensitive gene(s), we assayed STAG2, XIAP and THOC2 mRNA and protein expression in lymphoblastoid cell lines (immortalized B-lymphocytes, LCLs) derived from one affected individual of each of the NSW, SA1, D57 and L70 families and five male controls. Compared with controls, STAG2 mRNA expression was increased in all four LCLs derived from the affected individuals, while XIAP expression was higher in LCLs from the NSW, SA1 and D57 families, and THOC2 expression was elevated Fig. S1 ). Subsequent western blot analysis of cell lysates revealed increased amounts of STAG2 and XIAP protein in affected males from the NSW, SA1 and D57 families and only an elevated STAG2 level in the affected male from family L70 (Fig. 3 ). In contrast, THOC2 protein levels remained unchanged in all LCLs, including the NSW and D57 families, which carry THOC2 duplications (Fig. 3 ). This suggests that normal THOC2 protein levels in these LCLs are maintained by other means. We have evidence that post-translational regulation, potentially through proteasome-mediated degradation given THOC2 has been shown to be ubiquitylated (20) , might be involved (21) . Taken together, these results suggest that THOC2 is not implicated in the phenotype associated with Xq25 copy number gains. XIAP involvement cannot be fully excluded, but it is less likely given the individual from family L70 who has normal XIAP protein levels (see Fig. 3B ). Therefore, we hypothesized that copy number gains of STAG2 alone could be responsible for the phenotype.
Transcriptome is dysregulated in patient-derived cells
To test our hypothesis, we performed transcriptome analysis on LCL-derived mRNA of one affected male from the NSW, D57, SA1 and L70 families and five male controls. We and others have demonstrated that RNA-seq analysis on patient-derived cells can provide meaningful results for the understanding of normal brain function and development (22, 23) . RNA-seq analyses showed that in comparison with control LCLs, 214 genes were significantly dysregulated (126 up-and 88 down-regulated; false discovery rate (FDR) < 0.1) in the four LCLs with Xq25 duplication or triplication (Supplementary Material, Table S2 ). We validated our RNA-seq analyses by testing a set of dysregulated genes using real-time reverse transcriptase (RT)-qPCR (Figs. 4 and 5A ).
These included SLCO4C1 (log 2 fold change −1.5, P < 0.01), encoding solute carrier organic anion transporter (OATP) family member 4C1, a member of the OATP family, which is involved in membrane transport of bile acids, conjugated steroids, thyroid hormone, eicosanoids, peptides and numerous drugs in many tissues (25) ; CMTM7 (log 2 fold change 3.4, P < 4.5 × 10 −6 ), encoding CKLF-like marvel transmembrane domain-containing 7 the exact function of which is unknown (26); and OPHN1 (log 2 fold change 4.1, P < 3 × 10 −5 ), encoding a Rho-GTPase-activating protein, important for dendritic morphogenesis and synaptic function (Fig. 5A ). Compared with the controls, LCLs with duplications showed significantly higher OPHN1 expression, which was even higher in SA1 LCLs with a XIAP-STAG2 triplication (Fig. 5A ). OPHN1 is a known disease gene, whose loss-of-function mutations are responsible for XLID with cerebellar hypoplasia and distinctive facial dysmorphisms. To investigate whether increased OPHN1 expression results from higher cellular levels of STAG2, XIAP or both, we measured the levels of OPHN1 mRNA in HEK293T cells overexpressing epitope-tagged STAG2, XIAP or vector only. Significant increase in OPHN1 mRNA was observed in STAG2, but not XIAP overexpressing HEK293T cells (Fig. 5B) . These results suggest that the clinical phenotype associated with Xq25 gains could at least partly be due to OPHN1 overexpression.
Copy number gains dysregulate disease-relevant neuronal gene networks in patient-derived cells
To determine the biological and functional relevance of the significantly dysregulated genes in LCLs from the affected Table S2 ). This analysis identified networks of genes with functions in development of neurons (P < 0.0008), neuron viability (P < 0.002), seizures (P < 0.0002), disorder of basal ganglia (P < 0.001), neuronal cell death (P < 0.0003), formation of forebrain (P < 0.001) and movement disorders (P < 0.0001); neurological disease, cell-to-cell signaling, and interaction and inflammatory response (Network 3) and neurological disease, organismal injury and abnormalities (Network 4) (Supplementary Material, Fig. S2 ). In an independent analysis using WEB-based GEne SeT AnaLysis Toolkit (27) , the differentially expressed genes were grouped into categories such as global developmental delay (17 genes), cognitive impairment (33 genes) and encephalopathy (4 genes). Finally, we observed several other genes with known involvement in neuronal processes among the differentially expressed genes. Mutations in many of these are associated with ID, developmental delay, epilepsy or neuropsychiatric disorders (e.g. COL4A2, GPR98, TSPAN7 or TUBB2B and 2A, Supplementary Material, Tables S2 and S3 ). Taken together, these results reinforce deleterious molecular and likely also cellular consequences of increased dosage of STAG2.
Discussion
We have identified 28 affected males (15 from our 6 unrelated families and 13 others; excluding cases from the DECIPHER database) with copy number gains at Xq25 that are associated with ID, behavioral problems, seizures, malar flatness and prognathism. The copy number gains involved one or more genes: STAG2 (28 cases), XIAP (17 cases), THOC2 (12 cases) and GRIA3 (1 case), Fig. S3 ). Probing for β-tubulin was used to confirm even loading of protein samples. The other half was used for extracting total RNA that was used for RT-qPCR assay to determine OPHN1 mRNA levels using a Taqman approach.
which are all expressed in the human brain (28) . One of the rarely duplicated genes is GRIA3, which encodes glutamate receptor ionotropic AMPA subunit 3. Loss of function of GRIA3 due to gene truncation by a chromosome translocation, missense variants, partial tandem duplication or a microduplication located 874 kb upstream of GRIA3 has been linked to bipolar affective disorder and XLID (8, 11, 12, 29, 30) . THOC2 protein functions as a component of the mRNA transcription/export (TREX) complex (31, 32) . TREX transiently binds the capped, spliced and processed mRNAs, allowing binding of additional proteins that facilitate export of mRNA from the nucleus to the cytoplasm (33) . While our data show that THOC2 loss-of-function variants cause XLID (21), the results of this study show that increased genomic dosage of THOC2 is probably not deleterious. Firstly, THOC2 is not duplicated in 16/28 affected males, and secondly, THOC2 protein level is not increased in the affected individuals with THOC2 duplications. XIAP (X-linked inhibitor of apoptosis), also called BIRC4, is a member of inhibitors of apoptosis family of proteins that, besides its major role in apoptotic regulation, performs diverse biological functions, mainly through its E3 ubiquitin ligase activity (34) . XIAP has a neuroprotective role; particularly in response to injury to the developing brain (35, 36) , its expression is reduced in Huntington's disease brain tissues (37) and lossof-function mutations cause X-linked lymphoproliferative syndrome (38) . XIAP expression is affected in all but one Xq25 duplication cases we tested, that of family L70, and in many other cases, XIAP was not even involved in the duplicated region. Based on our aggregate clinical, genetic, molecular and mRNA expression studies, we conclude that STAG2 is the dosage-sensitive gene in Xq25 microduplications. Detailed clinical assessment of the newly identified patients with Xq25 duplications as part of our study along with those reported earlier (Table 1 and Supplementary Material, Table S1 ) reinforces previously suggested phenotypic hallmarks (7, 10, (13) (14) (15) 19) . The question whether the individuals with different size Xq25 duplication and as such gene content are clinically different is highly relevant. While deriving firm conclusions will require more patients and extensive reevaluation of clinical data, patients with STAG2 gene only duplications appear to be generally less severely affected.
STAG2 codes for a subunit of the cohesin complex that is essential for many cellular functions such as sister chromatid cohesion and segregation (canonical roles) and maintenance of chromatin architecture, DNA replication, DNA repair and transcriptional regulation (non-canonical roles) (39) . Interestingly and very much in line with our results, cohesin also has multiple transcriptional roles and is tightly regulated. Minor changes in cohesin activity cause the NDD Cornelia de Lange syndrome (CdLS) that presents with phenotypic variability, including ID, facial dysmorphism, growth delay, limb abnormalities and other phenotypes (40, 41) . Notably, duplication involving the SMC1A gene, which encodes a cohesin complex subunit, is shown to be associated with growth retardation, muscular skeletal abnormalities and ID, all features seen in other cohesin disorders, CdLS is one such disorder (42) . Several studies indicate that cohesin regulates transcription by facilitating insulator and enhancer-promoter looping, and by controlling the transition of promoterproximal paused Pol II to efficient elongation (43) . STAG2, or in some cases STAG1, which is mutually exclusive with STAG2, is the only cohesin subunit interacting directly with the zinc finger DNA-binding protein CTCF. This interaction bridges cohesin with CTCF, which is required for cohesin-dependent insulation activity (44) and has also been directly and indirectly implicated in ID (45, 46) . Recently, deleterious variants of STAG1 have been reported in two individuals with ID, and in one of them, cognitive impairment is accompanied by behavioral problems including autism, anxiety, mood instability and aggressive outbursts (47, 48) . Cohesin also interacts with the mediator complex, a transcriptional coactivator and STAG1, which physically interacts with the pluripotency transcription factor Nanog (49) . Furthermore, gene mutations in core and regulatory cohesin proteins have been identified in a wide range of cancers, where STAG2 was the most frequently mutated gene (50) . Whereas many cancers were caused by STAG2-inactivating mutations that caused chromosomal instability, some cancer types with normal karyotype could only be explained by dysregulation of gene expression, and STAG2 mutations can be involved. Thus far no STAG2 loss-offunction or point mutations have been identified in individuals with NDD and more specifically in cohesin-associated syndromes like CdLS (51), apart from one de novo missense mutation picked up by the recent DDD UK study (52) . Taken together, tight regulation of cohesin core subunits and regulatory genes is essential for normal cell division and gene expression, and their dysregulation results in related NDDs termed cohesinopathies, although affected individuals have no overt defects in chromosome segregation; instead, they have altered gene expression in hundreds of genes, suggesting that the pathology of these disorders is independent of cohesin's role in sister chromatid cohesion. Given our results showing that many of the dysregulated genes of the affected individuals with STAG2 duplications are expressed in the brain and have critical roles in the development of the nervous system (Supplementary Material, Tables S2 and S3 and Fig. S2 ), we can speculate that STAG2 increased expression leads to another form of cohesinopathy.
Using RNA-Seq, we identified several differentially expressed genes in the lymphoblasts of the patients with Xq25 copy number gains. Among the most significantly dysregulated genes were those that have been implicated in various neurological disorders with ID, e.g. TUBB2B (OMIM #610031) and 2A (OMIM #615763), COL4A2 (OMIM #614483), GPR98 (OMIM #605472), TSPAN7 (OMIM #300210) or OPHN1 (OMIM #300486). We followed up on one of these, OPHN1, which we discovered to be up-regulated in LCLs from affected individuals of the NSW, D57, L70 and SA1 families. OPHN1 is highly expressed in the brain (53) and important for regulation of dendritic morphogenesis and synaptic plasticity (53) (54) (55) . Loss-of-function mutations in OPHN1 are responsible for syndromic XLID with cerebellar hypoplasia, variable epilepsy and distinctive facial dysmorphisms (56) . In contrast, individuals who carry a duplication including OPHN1 had a different and distinctive phenotype. A maternally inherited Xq12q13.1 duplication encompassing OPHN1, YIPF6 and STARD8 has been reported in a male with severe ID, language impairment and apparent dysmorphisms (57) . A duplication encompassing OPHN1, YIPF6, STARD8, EFNB1 and PJA1 has been reported in a male with speech delay, developmental delay and facial dysmorphic features (58) , and a large duplication (Xq12q13.3) including OPHN1 has been reported in severely affected male siblings with global developmental delay and autism (59) . These data are consistent with a hypothesis that higher OPHN1 expression in individuals carrying STAG2 copy number gains may contribute to their clinical presentations. Furthermore, OPHN1 overexpression in rat pyramidal neurons was shown to enhance AMPA receptor-mediated transmission, and significantly increased spine size without altering the spine density (54 Tables S2 and S3 ) also need to be considered and investigated in order to determine the most likely drivers of the clinical phenotype.
Broad diagnostic and research application of new genomic technologies has dramatically accelerated the discovery of microdeletions and microduplications associated with NDDs (60) . There are now many examples of dosage-sensitive loci showing both deletion and duplication phenotypes, with the deletion phenotypes typically more severe than the duplication phenotypes (61) (62) (63) . However, the identification of the dosage-sensitive gene (s) has been challenging. Our clinical, genetic and molecular data provide strong evidence that STAG2 is the dosage-sensitive gene that is responsible for a novel cohesinopathy with ID, behavioral problems and other clinical presentations seen with Xq25 copy number gains.
Materials and Methods
Generation and maintenance of LCLs
The Epstein-Barr virus (EBV)-immortalized B-cell lines (LCLs) were established from peripheral blood lymphocytes of patients and controls following published method (64) . Briefly, lymphocytes were isolated from 5 to 10 ml of whole blood using lymphoprep reagent following the manufacturer's protocol (GE Life Sciences, Australia) and cultured for a period of 2 weeks in RPMI 1640 (Sigma-Aldrich, NSW, Australia) supplemented with 20% fetal calf sera (FCS), 2 m -glutamine and 0.017 mg/ml benzylpenicillin in the presence of EBV and 0.001 mg/ml Cyclosporin A (Sigma). Once established, the LCLs were maintained in RPMI 1640 supplemented with 10% FCS, 2 m -glutamine and 0.017 mg/ml benzylpenicillin at the conditions 37°C with 5% CO 2 .
RNA-Seq and RT-qPCR analyses
Total RNA was isolated from LCLs derived from one affected individual of NSW, D57, SA1 and L70 and five control LCLs using Quick RNeasy mini kit (Qiagen, VIC, Australia). The cDNA libraries were prepared with the Illumina TruSeq LT protocol using 2 μg RNA per sample and sequenced on the Illumina HiSeq 2000 (Illumina, San Diego, CA, USA). Approximately, 80 million pair-end reads per sample were mapped to the Hg19 build of the human genome using Tophat (version 2.0.9). HTSeq (version 0.5.4p5) was used to generate the raw counts. Differentially expressed genes (FDR < 0.1) were identified by comparing the patients and controls using edgeR package (65) . RT-qPCR was used for validating the differentially regulated genes in LCLs from affected individuals using mRNA-specific primers or Taqman probes (Life Technologies, VIC, Australia) (Supplementary Material, Table S4 ). Total RNA reverse transcribed with SuperScript III reverse transcriptase (Life Technologies) was used for assaying the levels of OPHN1 expression by the Taqman approach. RNaseP was used as a housekeeping gene to normalize OPHN1 expression. SCLO4C1 and CMTM7 expression was assayed by RT-qPCR using SYBR Green master mix (Bio-Rad, NSW, Australia) using primers listed in Supplementary Material, Table S4 . HPRT1 was used as a housekeeping gene for normalizing SCLO4C1 and CMTM7 expression.
XIAP and STAG2 expression plasmids
pEGFP-STAG2 expression plasmid was purchased from Addgene (Number 31 972). pDsRed-monomer-C1-XIAP expression plasmid was generated by cloning human XIAP-coding sequence (PCR amplified from brain cDNA with hXIAP-EcoRI-F and hXIAPBamHI-R primers, Supplementary Material, Table S4 ) in-frame with the RFP coding sequence at EcoRI-BamHI sites of pDsRedmonomer-C1. Sequence was confirmed by Sanger sequencing using the BigDye Terminator v3.1 chemistry (Life Technologies).
Western blotting
Total LCL lysates were prepared in 50 m Tris-HCl pH 7.5, 250 m NaCl, 1 m EDTA, 50 m NaF, 0.1 m Na 3 VO 4 , 1× protease inhibitors (Roche, NSW, Australia) and 1% Triton X-100, resolved on 3-8% Tris-acetate (THOC2; Life Technologies) or 7% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (66) (XIAP or STAG2) gels, transferred to nitrocellulose membranes and probed with rabbit anti-XIAP (Cell Signaling, QLD, Australia), anti-STAG2 (Cell Signaling) or anti-THOC2 (Bethyl Laboratories, Montgomery, TX, USA) primary antibodies followed by donkey anti-rabbit-IgG-HRP secondary antibodies (Dako, VIC, Australia). Blots were probed with rabbit anti-β-tubulin (Abcam, VIC, Australia) to control for even loading of protein amounts. Proteins were detected by enhanced chemiluminescence reagents (GE Life Sciences).
Supplementary Material
Supplementary Material is available at HMG online.
